Landos Biopharma Inc Ordinary Shares LABP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LABP is a good fit for your portfolio.
News
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHRD, AA, FUSN, LABP
-
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LABP, ADTH, MODN, SCX
-
Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, JBT
-
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – DOMA, LABP, FUSN, CBNK
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FUSN, LABP, DOMA
-
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ADTH, LABP, FUSN
Trading Information
- Previous Close Price
- $22.84
- Day Range
- $22.18–22.18
- 52-Week Range
- $2.56–22.84
- Bid/Ask
- $22.15 / $22.56
- Market Cap
- $69.18 Mil
- Volume/Avg
- 764 / 26,032
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages. The company's pipeline includes NX-13, LABP-66, LAPB-73, LABP-69. The company's current focus and lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 19
- Website
- https://www.landosbiopharma.com
Valuation
|
Metric
|
LABP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
LABP
|
|---|---|
Quick Ratio | 6.00 |
Current Ratio | 6.09 |
Interest Coverage | — |
Quick Ratio
LABP
Profitability
|
Metric
|
LABP
|
|---|---|
Return on Assets (Normalized) | −46.80% |
Return on Equity (Normalized) | −52.71% |
Return on Invested Capital (Normalized) | −54.81% |
Return on Assets
LABP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qtmzkldq | Tnv | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fmjljht | Vvkxdp | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pcvrjvm | Xbmycd | $98.3 Bil | |
MRNA
| Moderna Inc | Jbsfgchh | Trfyt | $42.7 Bil | |
ARGX
| argenx SE ADR | Fdqdcxys | Bywzx | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Szsgwvcp | Bnwx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dmgddfqq | Nkjkbt | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tjdzzmfmc | Sbryrq | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wdkxhzqk | Hvvjpzl | $12.7 Bil | |
INCY
| Incyte Corp | Wtxshnpk | Vysmwr | $11.8 Bil |